Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $34,471.20 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 4,240 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $34,471.20. Following the sale, the insider directly owned 206,210 shares of the company’s stock, valued at $1,676,487.30. The trade was a 2.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SOPHiA GENETICS Stock Performance

SOPH opened at $7.41 on Friday. The company’s 50 day moving average is $7.91 and its 200 day moving average is $6.16. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company has a market cap of $621.62 million, a price-to-earnings ratio of -6.44 and a beta of 0.95. SOPHiA GENETICS SA has a 12-month low of $3.75 and a 12-month high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, equities research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently bought and sold shares of SOPH. AWM Investment Company Inc. purchased a new position in shares of SOPHiA GENETICS in the second quarter valued at about $9,809,000. Principal Financial Group Inc. grew its position in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the first quarter worth about $2,157,000. Sei Investments Co. bought a new stake in SOPHiA GENETICS during the 1st quarter valued at approximately $1,772,000. Finally, 1492 Capital Management LLC raised its stake in SOPHiA GENETICS by 8.4% during the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after purchasing an additional 17,406 shares during the period. 31.59% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on SOPH shares. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright boosted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, BTIG Research increased their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.